Gnubiotics Sciences Announces Funding from the Swiss Innovation Agency to Accelerate Development of Glycopeptide Mediated Immunotherapies against Solid Tumors

06 Jul 2022
www.biospace.com
CollaborateFirst in ClassImmunotherapyASCO
LAUSANNE, Switzerland--(BUSINESS WIRE)-- Gnubiotics Sciences, a biotech company pioneering the discovery and development of immunomodulatory glycopeptides, today announced that the Swiss Innovation Agency (Innosuisse) will support a research collaboration with the University Hospital Zürich to accelerate the development of Gnubiotics’ GLAAD technology in a range of solid tumors. The total project cost of CHF 1.4 million (USD 1.4 million) will be supported by the grant from Innosuisse as well as contributions from Gnubiotics. This press release features multimedia. View the full release here: (Graphic: Business Wire) Altered glycosylation of tumors is a signature of cancer development, making glycans an emerging target especially in immunotherapy resistant patient cohorts. The sponsored project will advance GNU201 and GNU101, as potential first-in-class immunotherapeutics that steer immune responses to control growth in solid tumors expressing altered O-glycan profiles thus responding to a critical need in non-responding patients. The multi-year project which will include dose-finding and key translational studies, forms a core part of a broader preclinical development plan that will support an Investigational New Drug Application (IND). “This support from Innosuisse and continued close collaboration with Prof. Michael Scharl`s group at the University Hospital Zürich provide further validation of our GLAAD platform, which holds great therapeutic potential for anti-PD-1 resistant and other non-responsive patient cohorts” stated Yemi Adesokan, Ph.D., Gnubiotics’s Chief Executive Officer. Gnubiotics presented compelling data recently at the 2022 American Society of Clinical Oncology (ASCO) annual meeting showing the effect of its glycopeptides platform in driving robust T-cell immune responses against anti-PD-1 resistant tumorsPD-1 resistant tumors in a colorectal cancer mouse model. Also announced recently, was a collaboration with the University of Pennsylvania to explore CAR-T therapy in combination with Gnubiotics’ glycopeptides to enhance CAR-T efficacy in solid tumors. About GLAAD Glycopeptides are the foundation of Gnubiotics’ GLAAD molecules. GLAAD relies on glycopeptides as providers of antigenicity and adjuvanticity to the immune system. Gnubiotics’ GLAAD candidates are made of a range of glycans uniquely bound to peptides and can act directly on immune cells and modulate the microbiome. Combined, these modes of action influence the immune system responses which opens new ways to address areas where the immune system plays a role, including oncology, inflammatory and infectious diseases. About Innosuisse Innosuisse is the Swiss Innovation Agency. Its role is to promote science-based innovation in the interest of the economy and society in Switzerland. Innosuisse especially promotes the partnership between academia and the market with innovation projectslaying the groundwork for successful Swiss start-ups as well as innovative products and services. View source version on businesswire.com: Contacts Yemi Adesokan, Ph.D. Chief Executive Officer Email: info@gnubiotics.com Source: Gnubiotics Sciences Smart Multimedia Gallery Photo (Graphic: Business Wire) Logo View this news release and multimedia online at:
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.